• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].

作者信息

Yamamoto H, Arita N, Ohnishi T, Hiraga S, Izumoto S, Taki T, Higuchi M, Hayakawa T, Shinkai H

机构信息

Dept. of Neurosurgery, Osaka University Medical School.

出版信息

Gan To Kagaku Ryoho. 1993 Jul;20(9):1227-30.

PMID:8333749
Abstract

MX2 x HCl is a new morpholino anthracycline derivative with molecular weight 622.07, and highly lipophilic. In the animal experiments, MX2 was found to cross the blood brain barrier after i.v. injection. Its distribution into the brain was increased by intracarotid injection. In the present study, we examined the distribution of MX2 into the cerebrospinal fluid (CSF) after i.v. administration (5 mg/kg) in normal rabbits. Five min after injection, plasma concentration of MX2 reached to the maximum level (4344.5 ng/ml). CSF concentration of MX2 was at the highest level (75.8 ng/ml) 10 min after injection, and thereafter decreased gradually in parallel with plasma concentration. At 5 hrs after injection, CSF concentration became 26.7 ng/ml, AUC half time of elimination, and mean residence time were 3093.8 ng.hr/ml, 4.57 hrs and 5.10 hrs in plasma and 212.3 ng.h/ml, 5.23 hrs and 7.14 hrs in CSF, respectively. These results indicate that MX2 is able to distribute into CSF after i.v. injection, and expected to be a new anticancer drug for brain and leptomeningeal tumors.

摘要

相似文献

1
[Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].
Gan To Kagaku Ryoho. 1993 Jul;20(9):1227-30.
2
[Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Gan To Kagaku Ryoho. 1993 Apr;20(5):631-5.
3
[Distribution and acute toxicity of a new morpholinoanthracycline, MX2, in normal rat brain after intra-arterial injection].[新型吗啉代蒽环类药物MX2动脉内注射后在正常大鼠脑内的分布及急性毒性]
Gan To Kagaku Ryoho. 1991 Mar;18(3):371-5.
4
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.盐酸MX2在晚期恶性疾病患者中的药代动力学和药效学。
Cancer Chemother Pharmacol. 1997;40(3):202-8. doi: 10.1007/s002800050647.
5
Effect of MX2, a new morpholino anthracycline, against experimental brain tumors.
Anticancer Res. 1990 May-Jun;10(3):735-9.
6
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.非格司亭对晚期恶性疾病患者盐酸MX2药代动力学的影响。
Cancer Chemother Pharmacol. 1998;41(5):423-6. doi: 10.1007/s002800050761.
7
[Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].一种新型蒽环类衍生物MX2对人胶质瘤细胞的抗肿瘤作用
Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 1):399-403.
8
[Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro].
No To Shinkei. 1995 Oct;47(10):969-73.
9
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.吗啉代蒽环类药物MX2对胶质瘤细胞体外细胞毒性的研究。
J Clin Neurosci. 2000 Jan;7(1):42-7. doi: 10.1054/jocn.1998.0131.
10
The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
Neurosurgery. 1995 Sep;37(3):471-6; discussion 476-7. doi: 10.1227/00006123-199509000-00015.

引用本文的文献

1
Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.鞘内注射MX2化疗用于治疗体内胶质瘤播散
J Neurooncol. 2000 Aug;49(1):41-7. doi: 10.1023/a:1006436911670.
2
Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.恶性胶质瘤患者放疗前使用KRN8602(MX2)的II期试验。
J Neurooncol. 2000 Jun;48(2):145-9. doi: 10.1023/a:1006482006138.
3
A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.新型吗啉代蒽环类衍生物KRN8602(MX2)用于复发性恶性胶质瘤患者的II期研究。
J Neurooncol. 1999 Apr;42(2):177-81. doi: 10.1023/a:1006118800753.
4
Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.吗啉代蒽环类药物3'-脱氨基-3'-吗啉代-13-脱氧-10-羟基洋红霉素(MX2)在体外对人肿瘤集落形成单位的活性。
Invest New Drugs. 1995;13(2):125-131. doi: 10.1007/BF00872860.